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abStract
backgrOund
Low molecular weight heparin (LMWH) has been suggested as safe, efficient and convenient anticoagulation for 
haemodialysis (HD) than unfractionated heparin (UFH), with fewer side effects. The objective of  this study was to 
compare LMWH with UFH during haemodialysis in patients with end-stage renal disease (ESRD) to obtain precise 
estimates of  clinically important outcomes, including bleeding rates and thrombosis of  the extracorporeal circuit.
MethOd
In this prospective, randomised, cross-over study we compared the safety, clinical efficacy and cost effectiveness of  
enoxaparin sodium with unfractionated heparin in 44 patients (31 males,13 females; mean age  53.7.9 ± 14.2 years) with 
end-stage kidney disease (ESKD) on regular haemodialysis. They were randomly assigned to either enoxaparin sodium 
(40mg) or standard heparin, and followed prospectively for 16 weeks (48 dialyses sessions) before crossing over to the 
alternate therapy for a further 16 weeks. Heparin anticoagulation was monitored using activated coagulation times. 
Clinical clotting and haemorrhaging were evaluated by visual inspection after blood draining of  the air trap, blood lines 
and dialysers. To determine whether the type of  anticoagulation had any effect on the adequacy of  dialysis using Kt/V 
and lipid profile were measured.
reSuLtS
The present study showed that, compared with UFH, the effect of  LMWH enoxaparin sodium on the number of  
haemorrhagic events (relative risk, 1.3; 95% CI: 0.317 - 5.613; p = 1.000), bleedings evaluated by vascular access 
compression time (weighted mean difference,  -0.65; 95% CI: -1.55 - 0.82), or extracorporeal circuit thrombosis 
(relative risk, 0.75; 95% CI: 0.284 - 1.984; p = 1.000) was not significant. There was no significant difference in Kt/V 
between the groups (1.5 ± 1.2 for enoxaparin sodium vs 1.4 ± 0.4 for heparin; p = 0.6).There was no significant 
differences in serum total cholesterol, LDL, HDL and TGs after using either anticoagulant.
cOncLuSiOn
Enoxaparin sodium should be considered as effective and safe as unfractionated heparin and is more convenient than 
UFH in haemodialysis patients. But, currently direct costs are about 28% more.
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intrOductiOn
Low molecular weight heparins (LMWH) are increasingly used 
for the prevention and treatment of  many thromboembolic 
disorders because they are as effective and more convenient 
than unfractionated heparin (UFH) (1). The predictable 
anticoagulant effect of  LMWH eliminates the need for 
routine laboratory monitoring, allowing many patients with 
thrombosis to be treated without hospital admission. Other 
advantages include lower incidences of  heparin-induced 
thrombocytopenia and osteoporosis compared with UFH.
Some important differences exist between LMWH and 
UFH. Unlike UFH, which inhibits factor Xa and thrombin 
equally, LMWH have greater activity against factor Xa. The 
anticoagulant effects of  LMWH therefore are monitored by 
measuring the ability of  plasma from patients who are treated 
with LMWH to inhibit factor Xa; the resultant assay is known 
as an anti-Xa heparin level. This level reflects the amount of  
LMWH present in the blood and, by extension, the degree 
of  anticoagulation. Although the minimal therapeutic anti-
Xa level has not been established, a conservative therapeutic 
range measured 4h after a subcutaneous dose is 0.6 - 1.0 IU/
ml for twice-daily administration and 1.0 - 2.0 IU/ml for 
once-daily dosing (2).
Another important difference is that UFH is cleared 
through hepatic and renal mechanisms, whereas LMWH 
are dependent on renal clearance. Thus, patients with renal 
failure are potentially at risk for bleeding as a result of  
impaired LMWH clearance and prolonged anticoagulant 
effects. Observational studies and randomised trial data 
report increased bleeding using LMWH in patients with 
renal insufficiency compared with those without renal 
impairment (3,4,5,6). Moreover, LMWH are more expensive 
in comparison to UFH (7).
LMWH have high bioavailability, and supposedly less 
complications as they do not bind to plasma proteins, 
platelets, and endothelium as much as heparin does (8). It 
appears that LMWH do not stimulate plasma lipase activity 
to the same extent as UFH(9).
Despite the fact that LMWH are infrequently used for 
therapeutic anticoagulation in patients who require 
haemodialysis, they are used to prevent thrombosis of  the 
extracorporeal dialysis circuit. LMWH are not removed 
from the plasma during haemodialysis (10) or continuous 
veno-venous haemofiltration (11). Thus, LMWH pose a risk 
of  bioaccumulation and bleeding when used repeatedly for 
haemodialysis. Randomised controlled trials have evaluated 
LMWH for preventing thrombosis of  the dialysis circuit 
and are approved for this indication in many countries.
The objective of  this study was to compare LMWH 
with UFH during haemodialysis in patients with ESRD 
to obtain precise estimates of  clinically important 
outcomes, including bleeding rates and thrombosis of  the 
extracorporeal circuit. 
patientS and MethOdS 
Our prospective, randomised, cross-over study included 44 
adult patients (31 males, 13 females; mean age  53.7.9 ± 
14.2 years) with ESKD  on regular haemodialysis in the 
Theodor Bilharz Research Institute (TBRI), Cairo, Egypt. 
Informed consent was obtained from all participants.
Patients received haemodialysis three times a week for 4h 
per session at blood flow rates of  250-300ml/min, mainly 
with polysulfone membrane dialysers. Vascular access was 
via arteriovenous fistula. 
Exclusion criteria: 
1.  Patients with known bleeding disorders.
2.  Patients receiving oral or other forms of  
anticoagulant therapy (eg, warfarin, aspirin). 
Patients continued their usual medication (including lipid-
lowering therapy). Human recombinant erythropoietin was 
given where necessary to maintain target haemoglobin of  
11 - 12g/dl.
Patients were randomly assigned to continue receiving 
standard sodium heparin and followed prospectively for 16 
weeks (48 dialyses). The same patients were then crossed 
over to enoxaparin sodium (Clexane; 40mg)  and followed 
for a further 16 weeks (48 dialyses).
Heparin (sodium heparin 5000 IU/ml) was administered as 
a bolus dose (50 IU/kg body weight) intravenously into the 
pre-dialyser arterial line of  the extracorporeal blood circuit, 
followed by a maintenance dose of  1000 IU sodium heparin 
per hour. Infusion was discontinued 1h prior to cessation 
of  HD. LMWH, enoxaparin sodium (Clexane; 40mg) was 
administered three to four minutes before dialysis as a 
bolus dose, into the arterial line pre-dialyser. Monitoring of  
anticoagulation was carried out by visual inspection of  the 
arterial bubble trap every 30 to 60 minutes, as well as the 
blood lines and the dialyser after the session.
For evaluating the efficacy of  anticoagulation, the frequency 
and degree of  clot and fibrin formation in both the dialyser 
and lines were scored on a four-point scale, with one 
indicating no clot formation and four indicating severe 
clotting or total occlusion. This assessment was done after 
the blood had been returned to the patient by flushing 
the dialyser and lines with normal saline. Haemorrhage or 
thrombosis, during and between dialyses, was also noted. 
Clinical clotting and haemorrhage were evaluated by visual 
inspection.
Haemorrhages were categorised as weak, moderate, and 
severe. The dialysis adequacy – evidenced by Kt/V.
Fasting standard lipid profiles were determined at the 
end of  each arm of  the study. Total cholesterol (TC), low 
density lipoprotein (LDL), high density lipoprotein (HDL), 
and triglycerides (TG) were measured.
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StatiSticaL anaLySiS
Quantitative data are expressed as Mean ± Standard 
Deviation or percentage. There was no difference between 
the two sections of  the study, therefore data for each phase 
was pooled. The distribution of  variables was evaluated 
by the One-Sample Kolmogorov-Smirnov Test, and the 
differences between variables were determined using paired 
t-test for parametric data or Wilcoxon Signed Ranks Test 
for non-parametric data as appropriate. The analysis was 
performed using Statistical Analysis System, version 6.03, 
on an IBM personal computer and MedCalc for Windows 
(version 12.7.5). P value <0.05 was considered significant.
reSuLtS
The most causes of  ESRD were glomerulonephritis, 
diabetes mellitus and hypertension. Demographic 
characteristics of  the studied patients are shown in Table 1.
With UFH, clotting was noted in eight of  the 44 patients 
(18.2%) [Figure 1] and bleeding occurred in three of  the 
44 patients (6.1%) [Figure 2]. With enoxaparin sodium 
(40mg), clotting was noted in six of  the 44 patients (13.6%) 
[Figure 1] and bleeding occurred in four of  the 44 patients 
(9.1%) [Figure 2].
Compared with UFH, the effect of  LMWH on the number 
of  haemorrhagic events (relative risk, 1.3; 95% CI: 0.317 
- 5.613; p =1.000), bleedings evaluated by vascular access 
compression time (weighted mean difference, -0.65; 95% 
CI: -1.55 - 0.82), or extracorporeal circuit thrombosis 
(relative risk, 0.75; 95% CI: 0.284 - 1.984; p = 1.000) was 
not significant.
None of  the episodes of  clotting were severe enough 
to warrant change of  the dialyser or blood lines. None 
of  the bleeding episodes on enoxaparin required blood 
transfusions, and the bleeding could be controlled by 
venous compressions at the site of  the arteriovenous fistula.
To determine whether the type of  anticoagulation had any 
effect on the adequacy of  dialysis using Kt/V. There was 
no significant difference between the groups (1.5 ± 1.2 for 
Clexane vs 1.4 ± 0.4 for heparin; p = 0.6) [Table 2]. 
There was no significant differences in serum total, 
cholesterol, LDL, HDL and TGs after using either 
anticoagulant (Table 2).
By calculating the cost of  both anticoagulants, currently 
direct costs of  LMWH are about 28% more than UFH.
diScuSSiOn
The present study showed that, compared with UFH, 
the effect of  LMWH on the number of  haemorrhagic 
events (relative risk, 1.3; 95% CI: 0.317 - 5.613; p = 1.000), 
bleedings evaluated by vascular access compression time 
(weighted mean difference, -0.65; 95% CI: -1.55 - 0.82), or 
extracorporeal circuit thrombosis (relative risk, 0.75; 95% 
CI: 0.284 - 1.984; p = 1.000) was not significant.
Our results are consistent with a Meta-Analysis carried 
out by Lim et al where it was shown that the number of  
haemorrhagic events, bleedings assessed by vascular access 
compression time, or extracorporeal circuit thrombosis, 
are not significantly affected by LMWH (relative risk, 1.15; 
95% CI, 0.70 to 1.91) in comparison to UFH. Compared 
with UFH, LMWH appears to be as safe (in terms of  
bleeding complications) and as effective (in preventing 
extracorporeal circuit thrombosis). However, until larger, 
more exact randomised trials are conducted, no strong 
conclusion can be made from these trials assessing 
anticoagulation for patients who undergo haemodialysis 
(12).
Aggarwal et al showed that in contrast to UFH, the 
use of  enoxaparin sodium as an anticoagulant during 
haemodialysis, is associated with less platelet reactivity. 
Therefore, patients with ESRD treated with haemodialysis 
may benefit from enoxaparin sodium administration, as it 
decreases the risk of  cardiac events (13).
Lim et al in another Meta-Analysis of  11 randomised trials 
demonstrated that in patients with severe renal insufficiency 
(creatinine clearance ≤30 mL/min) compared with those 
without (creatinine clearance >30 mL/min), the use of  a 
standard therapeutic-dose LMWH (enoxaparin sodium) 
leads to higher levels of  anti-Xa. Consequently there is a 
two- to threefold increase in the risk of  major bleeding 
events (14).
Lim found that, compared with UFH, the effect of  LMWH 
on the number of  haemorrhagic events (relative risk, 0.96; 
95% CI: 0.27 - 3.43), bleedings evaluated by vascular access 
compression time (weighted mean difference, -0.87; 95% 
CI: -2.75 - 1.02), or extracorporeal circuit thrombosis 
(relative risk, 1.15; 95% CI: 0.70 - 1.91) was not significant. 
In comparison to UFH, LMWH has the same amount of  
efficacy in preventing extracorporeal circuit thrombosis 
and is as safe in terms of  bleeding complications. However, 
drawing strong conclusions from these trials assessing 
anticoagulation for patients who undergo haemodialysis 
requires more rigorous randomised trials (14).
In a study Guillet suggests that in haemodialysis patients 
there is an increased risk of  bleeding up to 10 hours after 
the injection of  LMWH enoxaparin sodium (15).
As reported by Saltissi, early in the use of  the enoxaparin 
sodium, minor interdialytic haemorrhaging (none requiring 
clinical intervention) increased among patients, which 
might be unnoticed until after four to eight dialyses. 
There was no difference in the frequency of  bleeding or 
thrombosis between the groups (16).
In a review article, Schmid proposed a detailed approach 
for LMWH administration in patients with severe renal 
insufficiency. In brief, this approach included: evaluation 
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of  the patient’s renal function, imminent interventions, and 
general bleeding risk before prescribing LMWH. LMWH 
has higher efficacy and lower bleeding risks in general. In 
unstable patients, or patients who have a high tendency 
for haemorrhaging, IV UFH is preferred to SC LMWH, 
as IV UFH has a shorter half-life time, and can be quickly 
antagonised.
Schmid concluded that though LMWH might be considered 
in severe renal insufficiency patients, caution, choice and 
careful monitoring of  these patients are necessary (10).
The ease of  administration of  LMWH (single bolus 
pre-dialysis) and lack of  laboratory monitoring are its 
advantages (7, 16,18,19,20).
UFH, besides anticoagulation properties, releases 
lipoprotein lipase from its active site at the capillary 
endothelial surface (16).
In our study there was no significant differences in serum 
total cholesterol, LDL, HDL and TGs after using either 
anticoagulant, and there was also no significant difference 
in Kt/V values between the groups (1.5 ± 1.2 for Clexane 
vs 1.4 ± 0.4 for heparin; p = 0.6).
Al-Saran reported that over 24 weeks tinzaparin sodium 
resulted in less frequent dialyser and air trap clotting than 
UFH, and there was no change in serum lipid profile of  the 
patients. The dialysis single pool Kt/V was improved after 
six months of  tinzaparin use (1.40 ± 0.28 for tinzaparin 
versus 1.23 ± 0.28 for heparin)(21).
Saltissi also observed no effects on lipids over three months 
(15).
Spaia et al found significantly lower HDL and higher 
triglyceride concentrations after 33 months of  the LMWH 
treatment (20).
Sabry et al reported no statistically significant differences in 
serum lipids (cholesterol, LDL, triglyceride and HDL), Hb, 
white blood cells count and platelet count after changing 
from UFH to tinzaparin sodium (20).
cOncLuSiOn
Clexane should be considered as effective and safe as UFH 
and is more convenient than UFH in haemodialysis patients. 
However, currently direct costs are about 28% more.
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tabLe 1: deMOgraphic characteriSticS 
Of the Studied patientS
Variable Studied patients
(no.44)
age (years) 53.7.9 ± 14.2 (23-67)
Sex
Male
female
31 (70.45%)
13 (29.55%)
bMi (kg/m2) 23 ± 3.4 (18.2-28.6)
duration on dialysis 
(month)
14.6 ± 3.8 (2-54)
aetiology of  eSrd dM (12 patients)
hypertension (10 
patients)
glomerulonephritis 
(nine patients)
Lupus nephritis (four 
patients)
analgesic nephropathy 
(two patients)
apkd (two patients)
Unknown (five patients)
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tabLe 2: Lipid prOfiLe and kt/V, after 16 weekS Of ufh and enOxaparin SOdiuM
Variable after unfractionated heparin after enoxaparin sodium P value
Lipid profile
total cholesterol (mg/dl)
hdL-cholesterol (mg/dl)
tgs
132.7 ± 26.54
35.7 ± 9.8
138.3 ± 58.6
136.3 ± 27.8
34.7 ± 5.2
143.2 ± 56.8
p = 0.53
p = 0.55
p = 0.6
kt/V 1.4 ± 0.4 1.5 ± 1.2 p = 0.6
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figure 1: percentage Of cLOtting in patientS receiVing LMwh and ufh
figure 2: percentage Of bLeeding in patientS receiVing LMwh and ufh
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